Anti-Human MUC1 Recombinant Antibody (TAB-026ML) (CAT#: TAB-026ML)

• Reliable in ELISA
  We have been using Gatipotuzumab for ELISA, and it has provided consistent and reliable results. The optimal concentration was easy to determine, and the sensitivity is outstanding.
• High specificity in FC
  Flow cytometry with Gatipotuzumab has been very efficient. The antibody labeled MUC1-expressing cancer cells with high specificity, which facilitated our analysis significantly.
• Minimal cross-reactivity
  We noticed minimal cross-reactivity with non-human MUC1, which was expected but good to confirm. It's highly specific to human MUC1, as advertised.

1. Q 1: In particular, how does gatipuzumab interact with the MUC1 antigen in cancerous cells?

   A: Targeted by gatipuzumab, the MUC1 antigen's variable region is overexpressed in a large number of epithelial malignancies. It attaches itself to the protein in its hypoglycosylated form, facilitating efficient identification and remedial action.

2. Q 2: In which types of cancers has Gatipotuzumab shown the most efficacy in clinical trials?

   A: In clinical trials, gemcitabine has demonstrated exceptional efficacy against non-small cell lung cancer, ovarian cancer, and breast cancer. Tumor shrinkage and higher survival rates are evidence of its effectiveness.

3. Q 3: Is it possible to combine gatipotuzumab with other forms of treatment?

   A: Indeed, in order to improve therapeutic results, intratuzumab is frequently used in conjunction with radiation, chemotherapy, or other monoclonal antibodies. Patient response rates have improved with such combo medicines.

View the frequently asked questions answered by Creative Biolabs Support.